Status:
UNKNOWN
Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With Pulmonary Interstitial Disease
Lead Sponsor:
Yanfeng Hou
Conditions:
Dermatomyositis
Eligibility:
All Genders
18-70 years
Brief Summary
To detect the changes of lymphocyte subsets in peripheral blood of non-myopathic dermatomyositis with pulmonary interstitial disease, classical dermatomyositis with pulmonary interstitial disease, rhe...
Eligibility Criteria
Inclusion
- The experimental group met the diagnostic criteria of Sontheimer and was diagnosed as CADM with pulmonary interstitial disease.
- Control group 1: The diagnosis was consistent with the diagnostic criteria of Bohan and Perter classification system, and it was confirmed that dermatomyositis was combined with pulmonary interstitial disease;
- Control group 2: The diagnosis meets the classification criteria of systemic lupus erythematosus revised by the American College of Rheumatology (ACR) in 1997 and is confirmed as systemic lupus erythematosus combined with pulmonary interstitial disease, or the diagnosis meets the diagnostic criteria of rheumatoid arthritis introduced by ACR in 1987 or ACR in 2010 and is confirmed as rheumatoid arthritis combined with pulmonary interstitial disease.
- Age 18-70 years old;
- Have a good understanding of their own illness and physical condition, have self-knowledge, can communicate well with others;
- Voluntarily join the study, understand the significance of the experiment and the indicators to be measured, and sign the informed consent.
Exclusion
- Severe infection: fever, cough, phlegm, sore throat, abdominal pain, diarrhea, carbuncle and other skin and soft tissue infection and other clinical manifestations, blood routine white blood cell count beyond the normal range (10×109/L);
- Severe cardiovascular disease: including chronic heart dysfunction grade 3 or above and various arrhythmias;
- Infectious diseases: hepatitis active stage, AIDS, syphilis, etc.
- Tumor markers of patients suggest the possibility of tumor.
- Patients with neuromuscular disease, inflammatory bowel disease, functional gastrointestinal disease;
- The patient has other connective tissue diseases or disorders.
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06149039
Start Date
April 1 2023
End Date
June 30 2024
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yanfeng Hou
Jinan, Shandong, China, 250000